

Reference: FOI.ICB-2526/104

Subject: Biosimilar insulin switch programs

I can confirm that the ICB does hold the information requested; please see responses below:

QUESTION	RESPONSE
1) Has your ICB, or any of the places within your ICB, undertaken or supported any biosimilar insulin switch programs (for example, switching patients from NovoRapid to Trurapi)? We are not interested in individual patient switches, only if there have been any managed switch programs.	Yes
2) If you have not, are there any plans to?	N/A
3) If you have, can you detail which insulin you switched from and which to, and when this was done?	NovoRapid to Trurapi switch. This project started in financial year 2023/24 and continues ongoing.

The information provided in this response is accurate as of 4 July 2025 and has been approved for release by Geeta Iyer, Deputy Chief Medical Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.